Efficacy and safety of Qiweiqingyan aerosol in treatment of acute pharyngitis (lung-stomach excess-heat syndrome): a multicenter, randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15005991

Enrollment

Unknown

Registered

2015-02-11

Start date

2015-03-16

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pharyngitis

Interventions

1:Qiweiqingyan aerosol with new propellan

2:Qiweiqingyan aerosol with old propellant

3:Placebo aerosol with old propellant

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of acute pharyngitis; 2. Lung-stomach excess-heat syndrome in traditional Chinese medicine; 3. Within 48 hours of onset; 4. Baseline visual analogue scale score of 5 or more, and sore throat score by traditional Chinese medicine score of 6 or more; 5. Centor criteria <=1; 6. Aged 18 to 65 years old; 7. Patient must voluntarily give written, informed consent and report adverse events and concomitant medication for duration of study.

Exclusion criteria

Exclusion criteria: 1. Temprature greater than 38.5 Centigrade; 2. Use of any medication taken for relief of symptoms including sore throat prior to study initiation; 3. Current use of analgesic or anti-inflammatory regimen requiring treatment with analgesics, NSAIDs or steroids; 4. Chronic pharyngitis; 5. Patients with any suspected or known heart diseases; 6. Patient with severe primary disease of pulmonary, hepatic, renal, or hematological system, or other serious diseases affected the survival, such as cancer or AIDS; 7. Abnormality of myocardial markers test, echocardiogram abnormality, ALT or AST >1.5 times of normal upper limit, abnormality of serum creatine, white blood cell count 10*10^9/L, neutrophil granulocyte >80%; 8. Pregnancy or lactating women, or women who have birth plan; 9. Allergic constitution or known to be allergic to any component in Qiweiqingyan Aerosol; 10. Mental patients or legal disability; 11. Patients having participated or participating in the other trials in last 3 months; 12. To be considered unsuitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Time to complete resolution of sore throat;Relief rate of sore throat;	—

Secondary

Measure	Time frame
Resolution rate of sore throat;Time to relief of sore throat;Intensity of sore throat assessed by VAS;Change of TCM symptoms score;Change of clinical signs score;	—

Countries

ChinA

Contacts

Public ContactMao Bing

maobing@medmail.com.cn+86 18980601724

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026